Kamada (NASDAQ:KMDA) Raised to Strong-Buy at Wall Street Zen

Kamada (NASDAQ:KMDA) was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report released on Saturday.

A number of other research firms also recently commented on KMDA. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Kamada in a report on Wednesday, October 8th. HC Wainwright raised their price objective on Kamada from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $14.00.

Kamada Price Performance

KMDA opened at $7.02 on Friday. Kamada has a 12-month low of $5.54 and a 12-month high of $9.15. The stock has a market capitalization of $403.72 million, a PE ratio of 19.50, a P/E/G ratio of 0.75 and a beta of 0.92. The firm’s fifty day moving average price is $6.87 and its 200 day moving average price is $7.10.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). The company had revenue of $47.01 million for the quarter, compared to analyst estimates of $154.21 million. Kamada had a return on equity of 7.89% and a net margin of 11.70%. On average, equities research analysts forecast that Kamada will post 0.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in KMDA. NewEdge Advisors LLC lifted its stake in Kamada by 4.2% in the third quarter. NewEdge Advisors LLC now owns 52,668 shares of the biotechnology company’s stock valued at $366,000 after buying an additional 2,125 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Kamada by 201.0% in the 3rd quarter. Bank of America Corp DE now owns 61,565 shares of the biotechnology company’s stock worth $427,000 after acquiring an additional 41,111 shares during the period. Man Group plc acquired a new stake in shares of Kamada in the 3rd quarter worth about $199,000. Two Sigma Investments LP lifted its position in Kamada by 4.3% in the 3rd quarter. Two Sigma Investments LP now owns 109,589 shares of the biotechnology company’s stock valued at $761,000 after purchasing an additional 4,504 shares during the last quarter. Finally, ARK Investment Management LLC boosted its stake in Kamada by 1.2% during the 3rd quarter. ARK Investment Management LLC now owns 256,217 shares of the biotechnology company’s stock valued at $1,779,000 after purchasing an additional 2,943 shares during the period. 20.38% of the stock is currently owned by institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.